peptideNot FDA-approvedPrescription only (US)Approved and prescribed in parts of Europe, Asia and Latin America; not FDA-approved in the United StatesThe Cochrane stroke review concluded evidence was insufficient to recommend routine use
CerebrolysinBenefits, Dosage & Interactions
Cerebrolysin is a peptide preparation derived from porcine brain proteins. It consists of biologically active neuropeptides with molecular weights below 10,000 daltons, mimicking the action of endogenous neurotrophic factors. Research on Cerebrolysin focuses on cognition and mood. Cerebrolysin is administered by injection rather than orally.
How much Cerebrolysin do people take?
The stroke Cochrane review pooled trials using 10 to 50 ml of Cerebrolysin by intravenous infusion daily. Route reported: Intravenous infusion in the trials pooled by both cited Cochrane reviews. Frequency reported: Once daily in most pooled trials. These are amounts documented in the cited studies and labels for Cerebrolysin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 62 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
62 human randomized trials published.
Plasma half-life
Not applicable
Default unit
ml
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The stroke Cochrane review pooled trials using 10 to 50 ml of Cerebrolysin by intravenous infusion daily[1][2]
Reported for Cerebrolysin in the cited sources. Published ranges are not dosing advice.
Mixing Cerebrolysin: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, Cerebrolysin vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the Cerebrolysin entry is written from. Each number matches an inline marker above.
- [1]Cerebrolysin for acute ischaemic strokeZiganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K · Cochrane Database of Systematic Reviews · 2023 · Peer-reviewed · PMID 37818733
- [2]Cerebrolysin for vascular dementiaCui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L · Cochrane Database of Systematic Reviews · 2019 · Peer-reviewed · PMID 31710397
What is Cerebrolysin studied for?
What is Cerebrolysin?
Cerebrolysin is a peptide preparation derived from porcine brain proteins. It consists of biologically active neuropeptides with molecular weights below 10,000 daltons, mimicking the action of endogenous neurotrophic factors. The preparation undergoes a standardized enzymatic breakdown process to ensure its composition. Its primary application has been in the treatment of various neurological and psychiatric disorders, particularly those involving cognitive impairment and neurodegeneration. Cerebrolysin is available as an injectable solution and is administered parenterally. It is not approved for use in all countries, and its regulatory status varies globally. In some regions, it is a prescription-only medication used under medical supervision, while in others, it is considered a dietary supplement.
What does the research say about Cerebrolysin?
Tap a section to expand.
Cerebrolysin's mechanism of action is complex and multifactorial, involving several pathways that support brain health and neuronal function. It is believed to act like natural neurotrophic factors, which are proteins that stimulate neurons to survive, differentiate, and grow. Key proposed mechanisms include:
* **Neuroprotection:** Cerebrolysin may protect neurons from damage caused by ischemia (reduced blood flow), excitotoxicity (overstimulation by neurotransmitters like glutamate), and oxidative stress. It is thought to reduce the formation of free radicals and modulate inflammatory responses in the brain.
* **Neurorestoration and Neurogenesis:** It has been suggested to promote neuronal repair and regeneration (neurogenesis) by enhancing protein synthesis in nerve cells. This can contribute to the formation of new synapses and improve neural connectivity.
* **Synaptogenesis:** Cerebrolysin may enhance the formation and maturation of synapses, which are the junctions between neurons where information is transmitted. Improved synaptic plasticity is crucial for learning and memory.
* **Modulation of Neurotransmitters:** Research indicates that Cerebrolysin can influence the activity of various neurotransmitter systems, including cholinergic, glutamatergic, and monoaminergic systems, which are vital for cognitive functions and mood regulation.
* **Energy Metabolism:** It may improve glucose utilization and energy metabolism in brain cells, which is essential for maintaining optimal neuronal function, especially under stress conditions. (PubChem)
These combined actions suggest that Cerebrolysin works to support the overall health, resilience, and functional capacity of the brain, particularly in the context of neurological insults or degenerative processes.
Cerebrolysin has been investigated for a range of potential benefits, primarily in the context of neurological conditions and cognitive decline. Research suggests it may offer:
* **Improved Cognitive Function:** Studies, particularly in patients with stroke, traumatic brain injury (TBI), and Alzheimer's disease, have shown potential for Cerebrolysin to improve cognitive domains such as memory, attention, and executive function. (Cochrane, 2010; DrugBank)
* **Neuroprotection and Recovery Post-Stroke:** In acute ischemic stroke, Cerebrolysin has been studied for its potential to reduce neurological deficits and improve functional outcomes by limiting neuronal damage and promoting recovery processes. (Cochrane, 2010)
* **Support in Alzheimer's Disease and Vascular Dementia:** Some clinical trials indicate that Cerebrolysin may slow the progression of cognitive decline in patients with mild to moderate Alzheimer's disease and vascular dementia, although results are not universally conclusive across all studies. (DrugBank)
* **Recovery from Traumatic Brain Injury (TBI):** There is evidence suggesting Cerebrolysin may aid in recovery following TBI by promoting neuroprotection and neurorestoration, potentially leading to better neurological and cognitive outcomes. (DrugBank)
* **Mood and Motivation Improvement:** Beyond cognitive effects, some patients receiving Cerebrolysin have reported improvements in mood, motivation, and activities of daily living, possibly due to its broad effects on brain function. (PubChem)
It is important to note that while some studies show promising results, especially in regions where Cerebrolysin is more commonly used, the strength of evidence and its widespread acceptance vary. Further rigorous research is ongoing to fully establish its efficacy and safety profile for various indications.
Cerebrolysin has been the subject of numerous clinical studies, particularly in Eastern Europe and Asia, for its use in stroke, dementia, and traumatic brain injury. A 2010 Cochrane review on Cerebrolysin for acute ischemic stroke concluded that, despite some promising results from trials of variable methodology, the evidence was insufficient to draw firm conclusions regarding its efficacy and safety due to methodological limitations and potential publication bias in the included studies. The review called for more high-quality, large-scale randomized controlled trials. (Cochrane, 2010)
For Alzheimer's disease and vascular dementia, several meta-analyses and individual studies have suggested a positive effect on global clinical impressions and cognitive scores, particularly with long-term administration. For example, a meta-analysis published in 2014 in the journal *CNS Neuroscience & Therapeutics* concluded that Cerebrolysin was associated with improved cognitive function and global clinical impression in Alzheimer's patients. However, methodological quality and heterogeneity among studies remain considerations for interpretation. (PubMed, independent research)
DrugBank notes that clinical trials have indicated neuroprotective and neurorestorative effects in various neurological disorders, including stroke, dementia, and brain injury. The FDA has not approved Cerebrolysin for use in the United States, citing insufficient evidence of efficacy and safety from trials conducted to current FDA standards. (DrugBank)
Overall, while there is a body of research indicating potential benefits, especially in acute neurological insults and neurodegenerative diseases, there is also a call for more robust, independently funded, and international multi-center trials to solidify its evidence base to meet global regulatory standards.
Commonly reported side effects of Cerebrolysin, primarily associated with its intravenous or intramuscular administration, include:
* **Gastrointestinal disturbances:** Nausea, vomiting, diarrhea, or constipation.
* **Headache:** Mild to moderate headaches.
* **Dizziness:** Feelings of lightheadedness or vertigo.
* **Injection site reactions:** Pain, redness, or inflammation at the site of injection.
* **Agitation or excitement:** Changes in mood or increased restlessness.
* **Insomnia:** Difficulty sleeping.
* **Sweating:** Increased perspiration.
* **Flu-like symptoms:** Fever or chills.
Less common but more serious side effects may include allergic reactions (ranging from rash to anaphylaxis), palpitations, or transient increases in blood pressure. If any severe or persistent side effects occur, medical attention should be sought immediately. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Individuals considering Cerebrolysin should be aware of several warnings:
* **Allergic Reactions:** As a protein-derived product, there is a risk of allergic reactions, including anaphylaxis, though rare. Patients with known allergies to similar protein components should exercise caution.
* **Pre-existing Conditions:** Caution is advised in patients with severe kidney impairment due to potential accumulation of peptide fragments. Use in patients with epilepsy, particularly grand mal seizures, should be carefully considered, as some studies have reported increased seizure frequency in susceptible individuals. (EMA SmPC, 2011)
* **Pregnancy and Lactation:** There is insufficient data on the safety of Cerebrolysin during pregnancy and lactation. Therefore, its use in these populations is generally not recommended unless the potential benefits clearly outweigh the risks, and under strict medical supervision.
* **Driving and Operating Machinery:** While Cerebrolysin typically does not impair these abilities, individuals should be aware of potential side effects like dizziness that could affect their capacity to perform such tasks safely.
* **Administration:** Cerebrolysin should only be administered by trained healthcare professionals, especially for intravenous infusions, to minimize risks associated with improper administration. (EMA SmPC, 2011)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Cerebrolysin is contraindicated in several situations where its use could be harmful or carries significant risk:
* **Acute Severe Renal Impairment:** Due to its elimination pathway, it is contraindicated in severe kidney failure, though specific creatinine clearance cutoffs may vary by regional guidelines. (EMA SmPC, 2011)
* **Epilepsy and Status Epilepticus:** Patients with a history of recurrent seizures or current status epilepticus should generally avoid Cerebrolysin, as it has been reported to potentially increase seizure activity in some individuals. (EMA SmPC, 2011)
* **Known Hypersensitivity:** Individuals with a known allergy or hypersensitivity to Cerebrolysin, its components, or similar protein products should not use it.
* **Acute Hemorrhagic Stroke:** While some studies investigate its role in stroke recovery, a significant contraindication is in the acute phase of hemorrhagic stroke (bleeding in the brain), where its effects on blood vessels could theoretically be detrimental. However, in ischemic stroke, it is used, highlighting the differentiation required.
* **Severe Psychiatric Disorders with Prodromal Symptoms of Psychosis:** Due to potential for psychiatric side effects like agitation, it's contraindicated in some severe psychiatric conditions.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Due to potential interactions and compatibility issues, Cerebrolysin should not be mixed with certain substances or administered concurrently with others:
* **Amino Acid Solutions:** Cerebrolysin is incompatible with balanced amino acid solutions due to potential interaction that can lead to precipitation or inactivation. It should not be mixed in the same infusion bag.
* **Lipid Emulsions:** Similar to amino acid solutions, mixing with lipid emulsions is contraindicated.
* **Solutions Affecting Protein Stability:** Avoid mixing Cerebrolysin with any solutions that are known to alter protein stability or that have a pH outside the physiological range of 7.0-7.4, as this could lead to denaturation or precipitation of the peptides.
* **Certain Medications:** Due to its complex composition, concurrent administration with certain medications, especially those affecting CNS activity, should be closely monitored by a clinician. While comprehensive interaction lists are not widely accessible, clinicians should exercise caution based on the patient's full medication regimen. (EMA SmPC, 2011)
In general, it is advisable to administer Cerebrolysin separately, using a dedicated intravenous line, and to avoid mixing it with any other medications or solutions unless specifically stated by the manufacturer or a licensed healthcare professional. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Cerebrolysin's typical timing for administration can be broadly categorized as any, meaning it is not strictly tied to specific times of day relative to meals or sleep cycles. However, the exact timing and frequency of administration (e.g., daily over several weeks, or as part of a cyclical treatment plan) are highly dependent on the specific neurological condition being treated, the severity of the condition, and individual patient response. For example, in acute stroke, treatment might commence as soon as possible after the event and continue for a specified duration. For chronic conditions like dementia, treatment might involve longer courses with periods of rest in between. The half-life is approximately 24 hours. Dosage is user-directed and must be set by a licensed clinician, who will also determine the appropriate timing and duration of the treatment course. Cerebrolysin can be administered either with or without food. It is primarily administered via injection (intravenous or intramuscular), so dietary intake does not generally influence its absorption or efficacy. The method of administration (e.g., slow intravenous infusion or intramuscular injection) also affects the immediate experience and practical timing.
Put it into practice
Reading about Cerebrolysin is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Cerebrolysin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Cerebrolysin
Cerebrolysin is a peptide preparation derived from the enzymatic breakdown of purified porcine (pig) brain proteins. It contains a mixture of biologically active neuropeptides.
No, Cerebrolysin's regulatory status varies significantly by country. It is approved and widely used in some regions, particularly in Eastern Europe and Asia, for neurological conditions. However, it is not approved by agencies like the U.S. FDA, which cites insufficient evidence based on their standards.
Cerebrolysin is an injectable solution. It can be administered intravenously (IV) as a slow infusion or intramuscularly (IM), depending on the prescribed dose and clinical context. Administration should always be performed by a qualified healthcare professional.
No, Cerebrolysin is not available as an oral formulation because its peptide components would likely be broken down by digestive enzymes before they could be absorbed and become active. It must be administered parenterally (by injection).
Cerebrolysin is primarily investigated and used for various neurological conditions, including acute ischemic stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer's disease and vascular dementia, with the aim of promoting neuroprotection and recovery.
As a peptide, Cerebrolysin can overlap with other supplements, prescription medicines, hormones and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Cerebrolysin with no sign-up.
Cerebrolysin is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Amounts for this peptide vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether Cerebrolysin fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Cerebrolysin. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Cerebrolysin varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Cerebrolysin depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Cerebrolysin the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
The stroke Cochrane review pooled trials using 10 to 50 ml of Cerebrolysin by intravenous infusion daily. Route reported: Intravenous infusion in the trials pooled by both cited Cochrane reviews. Frequency reported: Once daily in most pooled trials. These are amounts documented in the cited studies and labels for Cerebrolysin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Cerebrolysin?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Cerebrolysin for acute ischaemic stroke(opens PubMed in a new tab)Cochrane Database Syst Rev · 2023 · PMID 37818733 · https://pubmed.ncbi.nlm.nih.gov/37818733/
- 2.Cerebrolysin for vascular dementia(opens PubMed in a new tab)Cochrane Database Syst Rev · 2019 · PMID 31710397 · https://pubmed.ncbi.nlm.nih.gov/31710397/
- 3.Cerebrolysin for acute ischaemic stroke(opens PubMed in a new tab)Cochrane Database Syst Rev · 2015 · PMID 26083192 · https://pubmed.ncbi.nlm.nih.gov/26083192/
- 4.Cerebrolysin for acute ischaemic stroke(opens PubMed in a new tab)Cochrane Database Syst Rev · 2017 · PMID 28430363 · https://pubmed.ncbi.nlm.nih.gov/28430363/
Verify at
Publisher search links for Cerebrolysin. These are places to check the information — they are not citations, so they are not numbered.
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Cerebrolysin?
Plain-text summary, safe to quote verbatim:
Cerebrolysin is a peptide preparation derived from porcine brain proteins. It consists of biologically active neuropeptides with molecular weights below 10,000 daltons, mimicking the action of endogenous neurotrophic factors. Research on Cerebrolysin focuses on cognition and mood. Cerebrolysin is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/cerebrolysin
Cerebrolysin cheat sheet
DoseRoutine cheat sheet · Peptide
Cerebrolysin
Cerebrolysin is a peptide preparation derived from porcine brain proteins. It consists of biologically active neuropeptides with molecular weights below 10,000 daltons, mimicking the action of endogenous neurotrophic factors.
Evidence
Strong
62 human randomized trials published.
Studied range
The stroke Cochrane review pooled trials using 10 to 50 ml of Cerebrolysin by intravenous infusion daily
Route
Intravenous infusion in the trials pooled by both cited Cochrane reviews
Frequency studied
Once daily in most pooled trials
Half-life
Not established; Cerebrolysin is a mixture of peptide fragments without a single defined pharmacokinetic profile
Storage
Not reported in the cited reviews
Not FDA-approvedPrescription only (US)Approved and prescribed in parts of Europe, Asia and Latin America; not FDA-approved in the United StatesThe Cochrane stroke review concluded evidence was insufficient to recommend routine useBrain
Key references
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/cerebrolysin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Cerebrolysin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/cerebrolysin
What compounds are similar to Cerebrolysin?
Others in the peptide category or studied for the same goals.
Which goals is Cerebrolysin used for?
Other compounds studied for the same benefits as Cerebrolysin.
Continue exploring
See every compound DoseRoutine catalogs for these goals.